{
    "nctId": "NCT03445637",
    "briefTitle": "Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE\u00ae",
    "officialTitle": "Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE\u00ae",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasm",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 540,
    "primaryOutcomeMeasure": "Treatment-related adverse events during first 3 months",
    "eligibilityCriteria": "Inclusion Criteria\n\n* Women of \u226518 years of age with proven diagnosis of advanced/metastatic breast cancer (locoregionally recurrent or metastatic disease).\n* Estrogen Receptor+ (ER+) and/or Progesterone Receptor+ (PgR+) tumor based on local laboratory results (test as per local practice).\n* Human Epidermal Growth Factor Receptor 2 -(HER2-) breast cancer based on local laboratory results (test as per local practice or local guidelines)\n* Patients must be appropriate candidates for hormone therapy.\n* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n* During the post marketing surveillance (PMS) period, patients who initially administer IBRANCE\u00ae\n\nExclusion Criteria\n\n* Known hypersensitivity to letrozole or its excipients or to any Cyclin-Dependent Kinase 4/6 (CDK4/6) inhibitor excipients.\n* Pregnant women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}